Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Bioniche Life Sciences discontinues phase III Urocidin trial

Nov. 6, 2012

Siena Biotech presents new Wnt signaling inhibitors

Nov. 6, 2012

Bayer Schering Pharma synthesizes new protein kinase inhibitors

Nov. 6, 2012

Tesaro commences first clinical trial of its ALK inhibitor

Nov. 6, 2012

Hutchison MediPharma begins phase I study of novel EGFR inhibitor

Nov. 5, 2012

New CSF-1 receptor inhibitors divulged by Pharmascience

Nov. 5, 2012

Shanghai Allist Pharmaceutical patents new PI3K inhibitors

Nov. 5, 2012

Qilu Pharmaceutical discloses novel EGFR inhibitors

Nov. 5, 2012

Avastin obtains E.U. approval for recurrent, platinum-sensitive ovarian cancer

Nov. 2, 2012

Results presented from phase II trial of dovitinib in GIST

Nov. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...